These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 16628715)

  • 21. Tumor lysis syndrome following thalidomide and dexamethasone therapy for newly diagnosed multiple myeloma.
    Huston A; Brown J; Roodman GD
    Exp Hematol; 2006 Dec; 34(12):1616. PubMed ID: 17157156
    [No Abstract]   [Full Text] [Related]  

  • 22. Necrosis following skull base irradiation and stem cell transplant for multiple myeloma.
    Skamene S; Rotondo RL; Shustik C; Roberge D
    Am J Hematol; 2010 Sep; 85(9):713-4. PubMed ID: 20645432
    [No Abstract]   [Full Text] [Related]  

  • 23. Thalidomide in the treatment of multiple myeloma.
    Kastritis E; Dimopoulos MA
    Best Pract Res Clin Haematol; 2007 Dec; 20(4):681-99. PubMed ID: 18070713
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of thalidomide in previously untreated patients with multiple myeloma.
    Musto P; D'Auria F; Pietrantuono G; Bringhen S; Morabito F; Di Raimondo F; Pozzi S; Sacchi S; Boccadoro M; Palumbo A; ;
    Expert Rev Anticancer Ther; 2008 Oct; 8(10):1569-80. PubMed ID: 18925849
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CC-5013 MM 0017: a multicenter, randomized, parallel-group, double-blind, placebo-controlled study of CC-5013 plus dexamethasone versus dexamethasone alone in previously treated subjects with multiple myeloma.
    Clin Adv Hematol Oncol; 2003 Mar; 1(3):189-90. PubMed ID: 16224405
    [No Abstract]   [Full Text] [Related]  

  • 26. Recent advances in the mangement of multiple myeloma.
    Kumar L; Vikram P; Kochupillai V
    Natl Med J India; 2006; 19(2):80-9. PubMed ID: 16756196
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bendamustine in combination with thalidomide and dexamethasone is an effective therapy for myeloma patients with end stage renal disease.
    Ramasamy K; Hazel B; Mahmood S; Corderoy S; Schey S
    Br J Haematol; 2011 Dec; 155(5):632-4. PubMed ID: 21689088
    [No Abstract]   [Full Text] [Related]  

  • 28. Treatment options and considerations for the newly diagnosed myeloma patient.
    Rajkumar VS;
    Oncology (Williston Park); 2005 Sep; 19(10):1260, 1262, 1267 passim. PubMed ID: 16285223
    [No Abstract]   [Full Text] [Related]  

  • 29. Refractory multiple myeloma treated with homoharringtonine: report of two cases.
    Yang X; Yang C; Shao K; Ye X; Meng H; Zhou Y; Qian W
    Ann Hematol; 2007 Dec; 86(12):919-21. PubMed ID: 17641891
    [No Abstract]   [Full Text] [Related]  

  • 30. Lenalidomide in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma.
    Palumbo A; Dimopoulos M; San Miguel J; Harousseau JL; Attal M; Hussein M; Knop S; Ludwig H; von Lilienfeld-Toal M; Sonneveld P
    Blood Rev; 2009 Mar; 23(2):87-93. PubMed ID: 18774632
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel agents in myeloma: an exciting saga.
    Mark T; Niesvizky R; Coleman M
    Cancer; 2009 Jan; 115(2):236-42. PubMed ID: 19025986
    [No Abstract]   [Full Text] [Related]  

  • 32. Thalidomide plus monthly high-dose dexamethasone in chemorefractory myeloma. Results of a phase II clinical study.
    Bernardeschi P; Giustarini G; Montenora I; Turrisi G; Dentico P; Rossi S; Turano E; Fiorentini G
    In Vivo; 2006; 20(6A):719-20. PubMed ID: 17203753
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients.
    Morgan GJ; Schey SA; Wu P; Srikanth M; Phekoo KJ; Jenner M; Davies FE
    Br J Haematol; 2007 May; 137(3):268-9. PubMed ID: 17408469
    [No Abstract]   [Full Text] [Related]  

  • 34. [New trends in the therapy of myeloma].
    Jantunen E; Nousiainen T
    Duodecim; 2000; 116(9):937-9. PubMed ID: 11988994
    [No Abstract]   [Full Text] [Related]  

  • 35. Controversies regarding the use of dexamethasone in patients with multiple myeloma.
    Rajkumar SV
    Clin Adv Hematol Oncol; 2008 Feb; 6(2):103, 141. PubMed ID: 18347560
    [No Abstract]   [Full Text] [Related]  

  • 36. Lenalidomide: a new therapy for multiple myeloma.
    Palumbo A; Miguel JS; Sonneveld P; Moreau P; Drach J; Morgan G; Einsele H
    Cancer Treat Rev; 2008 May; 34(3):283-91. PubMed ID: 18230411
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lenalidomide: new drug. Myeloma: many questions remain unanswered.
    Prescrire Int; 2008 Dec; 17(98):230-2. PubMed ID: 19422142
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hypercoagulable states in patients with multiple myeloma can affect the thalidomide-associated venous thromboembolism.
    Talamo GP; Ibrahim S; Claxton D; Tricot GJ; Fink LM; Zangari M
    Blood Coagul Fibrinolysis; 2009 Jul; 20(5):337-9. PubMed ID: 19367157
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vincristine, doxorubicin, and dexamethasone or thalidomide plus dexamethasone for newly diagnosed patients with multiple myeloma?
    Jimenez-Zepeda VH; Domínguez-Martínez VJ
    Eur J Haematol; 2006 Sep; 77(3):239-44. PubMed ID: 16856924
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bortezomib in combination with dexamethasone and subsequent thalidomide for newly-diagnosed multiple myeloma: a Chinese experience.
    Zheng W; Wei G; Ye X; He J; Li L; Wu W; Shi J; Zhang J; Huang W; Xie W; Luo Y; Xue X; Lin M; Huang H; Cai Z
    Leuk Res; 2009 Dec; 33(12):1615-8. PubMed ID: 19773080
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.